Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 7/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | FUCA1 | P04066 | 7/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17352352 | 0.78 | EPHX2 (0.58) | GBA1EPHX2LMNASMN1; SMN2FUCA1 | |
| SCHEMBL17352418 | 0.74 | LMNA (0.55) | GBA1EPHX2LMNASMN1; SMN2 | |
| SCHEMBL11736631 | 0.71 | GBA1 (0.57) | GBA1FUCA1 | |
| SCHEMBL14119129 | 0.71 | CYP1A2 (0.30) | — | |
| SCHEMBL23970134 | 0.69 | EPHX2 (0.53) | GBA1EPHX2LMNASMN1; SMN2 | |
| SCHEMBL28633234 | 0.69 | EPHX2 (0.53) | GBA1EPHX2LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL29411691 | 0.68 | EPHX2 (0.51) | GBA1EPHX2LMNASMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL22163972 | 0.68 | EPHX2 (0.51) | GBA1EPHX2LMNASMN1; SMN2 | |
| SCHEMBL11585505 | 0.66 | FUCA1 (0.35) | GBA1FUCA1 | |
| SCHEMBL2614256 | 0.61 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0870757-B1 | Fluoro-substituted adamantane derivatives | PFIZER (US) | 2002-06-12 | — | — | EP | claimed |
| US-6057364-A | USED FOR TREATING NEUROLOGICAL DISORDERS, SUCH AS MEMORY LOSS AND PARKINSON'S DISEASE, AND BACTERIAL AND VIRAL INFECTIONS | PFIZER INC (US) | 2000-05-02 | — | — | US | claimed |
| EP-0870757-A2 | Fluoro-substituted adamantane derivatives | PFIZER INC. (US) | 1998-10-14 | — | — | EP | claimed |
| EP-0076755-B1 | ACYLAMINO-4-AZA-1-ADAMANTANES, PROCESS FOR THEIR PREPARATION AND THEIR THERAPEUTIC USE | ETABLISSEMENTS NATIVELLE S.A. (FR) | 1988-01-13 | — | — | EP | claimed |
| US-4578382-A | ANTIARRHYTHMIA AGENTS | ETABLISSEMENTS NATIVELLE S.A. (FR) | 1986-03-25 | — | — | US | claimed |
| US-20110201665-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2011-08-18 | — | — | US | disclosed |
| US-20110028510-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2011-02-03 | — | — | US | disclosed |
| WO-2011001258-A1 | COMPOSITIONS, METHODS, AND KITS FOR TREATING VIRAL AND BACTERIAL INFECTIONS BY TOCOTRIENOLS, TOCOMONOENOLS, TOCODIENOLS, TOCOPHEROLS, AND THEIR DERIVATES | EVITA LIFE SCIENCE PTE. LTD (SG) | 2011-01-06 | — | — | WO | disclosed |
| WO-2010095041-A2 | COMPOSITIONS, METHODS, AND KITS FOR TREATING INFLUENZA VIRAL INFECTIONS | EXCRX (SINGAPORE) PTE.LTD. (SG) | 2010-08-26 | — | — | WO | disclosed |
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | COMBINATORX, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006119295-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | COMBINATORX, INCORPORATED (US) | 2006-11-09 | — | — | WO | disclosed |
| EP-0870757-B1 | Fluoro-substituted adamantane derivatives | PFIZER (US) | 2002-06-12 | — | — | EP | disclosed |
| US-6057364-A | USED FOR TREATING NEUROLOGICAL DISORDERS, SUCH AS MEMORY LOSS AND PARKINSON'S DISEASE, AND BACTERIAL AND VIRAL INFECTIONS | PFIZER INC (US) | 2000-05-02 | — | — | US | disclosed |
| EP-0870757-A2 | Fluoro-substituted adamantane derivatives | PFIZER INC. (US) | 1998-10-14 | — | — | EP | disclosed |
| US-4578382-A | ANTIARRHYTHMIA AGENTS | ETABLISSEMENTS NATIVELLE S.A. (FR) | 1986-03-25 | — | — | US | disclosed |
| US-4578382-A | ANTIARRHYTHMIA AGENTS | ETABLISSEMENTS NATIVELLE S.A. (FR) | 1986-03-25 | — | — | US | disclosed |
| US-4578382-A | ANTIARRHYTHMIA AGENTS | ETABLISSEMENTS NATIVELLE S.A. (FR) | 1986-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270742-A1 | Compositions and methods for the treatment of neurodegenerative diseases | PSEN2, PSEN1, HTT | GBA1 27/4885EPHX2 1794/4885LMNA 166/4885 |
| US-20110201665-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | IL5, CCL5, CCL11 | GBA1 1526/4885EPHX2 1373/4885LMNA 641/4885 |
| US-20110028510-A1 | Compositions, Methods, and Kits for Treating Influenza Viral Infections | IL5, CCL5, CCL11 | GBA1 1526/4885EPHX2 1373/4885LMNA 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.